Annual ReportSee All
Application noteSee All
Affmer proteins are recombinant affinity reagents that exhibit high affinity and high specificity binding across a range of reaction conditions.
Avacta's unique technology enables Affimer® affinity resins to be developed to a range of molecules for affinity purification purposes.
We have developed Affimers to a recombinant form of the Zika virus NS1 protein that is diagnostic of Zika infection at the early, acute phase. In just 16 weeks we generated specific Affimer binders to this challenging target, and have demonstrated their effectiveness in ELISA/immunoassay format for specific detection of the Zika NS1 antigen at clinically relevant concentrations.
General MeetingsSee All
Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and research reagents, announces that at the Annual General Meeting held earlier
Notice of the annual general meeting of the Company to be held at the officces of FTI Consulting at 200 Aldersgate, Aldersgate Street, London EC1A 4HD on Friday 20 January 2017 at 10.00 a.m.
Interim AnnouncementsSee All
Interim Results Analyst Presentation 2016
Investor infoSee All
An analysis of Avacta's unaudited preliminary results for the year ending 31 July 2017 by Turner Pope.
An analysis of Avacta's unaudited preliminary results for the year ending 31 July 2017 by Capital Network.
This feature appeared in Shares Magazine in August 2017
This project aims to discover Affimer therapeutics that block hPD-1 / hPD-L1 and activate T-cells, preventing checkpoint inhibition. The conclusions are that:
Monoclonal antibodies have successfully shown that blocking cellular interactions that negatively regulate T-cell immune responses can amplify pre-existing immunity to cancer. Programmed death-ligand 1 (PD-L1) is a clinically validated oncology target shown to play an important role in down
Programmed death-ligand 1 (PD-L1) is clinically validated in oncology and shown to play an important role in down regulating the immune system allowing tumour cells to evade detection and metastasize.
Preliminary AnnouncementSee All
Please note: This file is an audio / video webcast and requires the WebEx ARF player to playback the recording. Download ARF player here.
Presentation given by Avacta's Chief Scientific Officer Dr Amrik Basran in June 2017.
Download presentationThe investor presentation accompanying the preliminary results for the period ended 31 July 2017 is available to download below.
Published PaperSee All
Damaged mitochondria undergo mitophagy, a specialized form of autophagy that is initiated by the protein kinase PINK1 and the ubiquitin E3 ligase Parkin.
Michel et al. describe linkage-specific tools for the study of atypical K6 and K33/ K11 ubiquitin linkages. Affimers have applications in western blotting, confocal microscopy, and pull-downs.
Glypican-3 (GPC3) is a promising new marker for hepatocellular carcinoma, but the reported values for serum GPC3 differ markedly between currently available kits.
Research NoteSee All
White paperSee All
New white paper examines a range of alternatives to antibodies This paper reviews the main applications of affnity binders and the requirements placed on them according to application.
This case study outlines Affimer technology for the generation of cancer immune checkpoint inhibitors, to demonstrate the rapid identification of a number of biotherapeutic candidate molecules.